Davis's Drug Guide. Tags Type your tag names separated by a space and hit enter. Citation Vallerand, April Hazard. Davis Company, Davis Company; Accessed November 11, Vallerand, A. In Davis's Drug Guide 16th edition. Davis Company. Furosemide [Internet]. In: Davis's Drug Guide. Your free 1 year of online access expired. Log in to Davis's Drug Guide. Forgot Your Password? Enter your username below and we'll send you an email explaining how to change your password.
Note: Your username may be different from the email address used to register your account. Aripiprazole: Minor Aripiprazole may enhance the hypotensive effects of antihypertensive agents. Arsenic Trioxide: Moderate Use caution when using arsenic trioxide concomitantly with loop diuretics, as these can cause electrolyte abnormalities, which can increase the risk of QT prolongation.
Asenapine: Moderate Secondary to alpha-blockade, asenapine can produce vasodilation that may result in additive effects during concurrent use of antihypertensive agents. The potential reduction in blood pressure can precipitate orthostatic hypotension and associated dizziness, tachycardia, and syncope. If concurrent use of asenapine and antihypertensive agents is necessary, patients should be counseled on measures to prevent orthostatic hypotension, such as sitting on the edge of the bed for several minutes prior to standing in the morning and rising slowly from a seated position.
Close monitoring of blood pressure is recommended until the full effects of the combination therapy are known. Aspirin, ASA; Butalbital; Caffeine; Codeine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with codeine.
Aspirin, ASA; Carisoprodol; Codeine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with codeine. Aspirin, ASA; Oxycodone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with oxycodone.
Atenolol; Chlorthalidone: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss. Atracurium: Moderate Furosemide-induced hypokalemia can potentiate neuromuscular blockade with nondepolarizing neuromuscular blockers. In addition, furosemide may antagonize the skeletal muscle relaxing effect of tubocurarine and can potentiate neuromuscular blockade following succinylcholine administration.
While glucocorticoids with mineralocorticoid activity e. Close monitoring of electrolytes should occur in patients receiving these drugs concomitantly. Azilsartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.
Azilsartan; Chlorthalidone: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.
Bacitracin: Minor Additive nephrotoxicity may occur with concurrent use of systemic bacitracin and other nephrotoxic agents. When possible, avoid concomitant administration of systemic bacitracin and other nephrotoxic drugs such as loop diuretics. Topical administration of any preparation containing bacitracin, especially when applied to large surface areas, also should not be given with other drugs that have a nephrotoxic potential.
Minor Additive nephrotoxicity may occur with concurrent use of these medicines. When possible, avoid concomitant administration of systemic bacitracin and loop diuretics.
Use of topically administrated preparations containing bacitracin, especially when applied to large surface areas, may have additive nephrotoxic potential with loop diuretics. Bacitracin; Hydrocortisone; Neomycin; Polymyxin B: Minor Additive nephrotoxicity may occur with concurrent use of systemic bacitracin and other nephrotoxic agents. Bacitracin; Neomycin; Polymyxin B: Minor Additive nephrotoxicity may occur with concurrent use of systemic bacitracin and other nephrotoxic agents.
Bacitracin; Polymyxin B: Minor Additive nephrotoxicity may occur with concurrent use of systemic bacitracin and other nephrotoxic agents. Baclofen: Moderate Baclofen has been associated with hypotension.
Concurrent use with baclofen and antihypertensive agents may result in additive hypotension. Dosage adjustments of the antihypertensive medication may be required. Belladonna; Opium: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with opium.
Benazepril: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure.
Benazepril; Hydrochlorothiazide, HCTZ: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Bendroflumethiazide; Nadolol: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss.
Benzhydrocodone; Acetaminophen: Moderate Benzhydrocodone may reduce the efficacy of diuretics due to induction of the release of antidiuretic hormone. In addition, opiate agonists may potentiate orthostatic hypotension when used concurrently with diuretics. Benzphetamine: Minor Benzphetamine may increase both systolic and diastolic blood pressure and may counteract the activity of some antihypertensive agents, such as loop diuretics.
Beta-agonists: Moderate Loop diuretics may potentiate hypokalemia and ECG changes seen with beta agonists. Hypokalemia due to beta agonists appears to be dose related and is more likely with high dose therapy.
Caution is advised when loop diuretics are coadministered with high doses of beta agonists; potassium levels may need to be monitored. Bisacodyl: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives.
Bisoprolol; Hydrochlorothiazide, HCTZ: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss. Bosentan: Moderate Although no specific interactions have been documented, bosentan has vasodilatory effects and may contribute additive hypotensive effects when given with diuretics. Brexpiprazole: Moderate Due to brexpiprazole's antagonism at alpha 1-adrenergic receptors, the drug may enhance the hypotensive effects of alpha-blockers and other antihypertensive agents.
Brompheniramine; Carbetapentane; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Brompheniramine; Guaifenesin; Hydrocodone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Brompheniramine; Hydrocodone; Pseudoephedrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Brompheniramine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Buprenorphine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with buprenorphine.
Buprenorphine; Naloxone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with buprenorphine.
Cabergoline: Minor Cabergoline has minimal affinity for adrenergic receptors; however, it has been associated with hypotension in some instances.
Cabergoline should be used cautiously in those receiving antihypertensive agents. Cabozantinib: Minor Monitor for an increase in cabozantinib-related adverse reactions if coadministration with furosemide is necessary. MRP2 inhibitors have the potential to increase plasma concentrations of cabozantinib; however, the clinical relevance of this interaction is unknown.
Calcium Carbonate; Magnesium Hydroxide: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives.
Calcium Phosphate, Supersaturated: Moderate Concomitant use of medicines with potential to alter renal perfusion or function such as diuretics, may increase the risk of acute phosphate nephropathy in patients receiving sodium phosphate monobasic monohydrate; sodium phosphate dibasic anhydrous. In addition, loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives.
Canagliflozin: Moderate When canagliflozin is initiated in patients already receiving diuretics, symptomatic hypotension can occur. Patients with impaired renal function eGFR Canagliflozin; Metformin: Moderate When canagliflozin is initiated in patients already receiving diuretics, symptomatic hypotension can occur.
Patients with impaired renal function eGFR Candesartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure. Candesartan; Hydrochlorothiazide, HCTZ: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.
Capreomycin: Moderate The risk of ototoxicity or nephrotoxicity secondary to capreomycin may be increased by the addition of concomitant therapies with similar side effects, including loop diuretics. Ototoxicity from furosemide or other loop diuretics, while uncommon, can be a transient or permanent side effect of significance. Ototoxicity is best documented with the loop diuretics ethacrynic acid and furosemide, but may also occur with either bumetanide or torsemide.
The exact mechanism by which furosemide or other loop diuretics produce ototoxicity is unknown. Usually, reports indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, higher than recommended dosages or infusion rates, or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If loop diuretics and capreomycin are used together, it would be prudent to monitor renal function parameters, serum electrolytes, and serum aminoglycoside concentrations during therapy.
Captopril: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure.
Captopril; Hydrochlorothiazide, HCTZ: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure.
Carbenicillin: Minor Furosemide may compete with penicillin for renal tubular secretion, increasing penicillin serum concentrations.
Carbetapentane; Chlorpheniramine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Carbetapentane; Diphenhydramine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Carbetapentane; Guaifenesin; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Carbetapentane; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Carbetapentane; Phenylephrine; Pyrilamine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Carbetapentane; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Carbidopa; Levodopa: Moderate Concomitant use of antihypertensive agents with levodopa can result in additive hypotensive effects. Carbidopa; Levodopa; Entacapone: Moderate Concomitant use of antihypertensive agents with levodopa can result in additive hypotensive effects.
Carbinoxamine; Dextromethorphan; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Carbinoxamine; Hydrocodone; Phenylephrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone.
Carbinoxamine; Hydrocodone; Pseudoephedrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Carbinoxamine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Carbinoxamine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Cardiac glycosides: Moderate Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics, increasing the risk of proarrhythmic effects of cardiac glycosides. Potassium levels should be monitored and normalized prior to and during concurrent diuretic administration and these agents.
Cariprazine: Moderate Orthostatic vital signs should be monitored in patients who are at risk for hypotension, such as those receiving cariprazine in combination with antihypertensive agents. Atypical antipsychotics may cause orthostatic hypotension and syncope, most commonly during treatment initiation and dosage increases. Patients should be informed about measures to prevent orthostatic hypotension, such as sitting on the edge of the bed for several minutes prior to standing in the morning, or rising slowly from a seated position.
Consider a cariprazine dose reduction if hypotension occurs. Casanthranol; Docusate Sodium: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives. Castor Oil: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives. Cefaclor: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Clinicians should be aware that this may occur even in patients with minor or transient renal impairment. Cefadroxil: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefazolin: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefdinir: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Cefditoren: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefepime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefixime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefoperazone: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Cefotaxime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefotetan: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Cefoxitin: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Cefpodoxime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefprozil: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Ceftaroline: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Ceftazidime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Ceftazidime; Avibactam: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Ceftibuten: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Ceftizoxime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Ceftolozane; Tazobactam: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Ceftriaxone: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefuroxime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Celecoxib: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.
Patients taking diuretics and NSAIDs concurrently are at higher risk of developing renal insufficiency. NSAIDs may reduce the natriuretic effect of diuretics in some patients. NSAIDs have been associated with an inhibition of prostaglandin synthesis, which may result in reduced renal blood flow leading to renal insufficiency and increases in blood pressure that are often accompanied by peripheral edema and weight gain.
Cephalexin: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cephalosporins: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cephalothin: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cephradine: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Cetirizine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Chlophedianol; Dexchlorpheniramine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Chlophedianol; Guaifenesin; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Chloral Hydrate: Major According to the manufacturer, coadministration of furosemide with chloral hydrate is not recommended.
Intravenous administration of furosemide within 24 hours of taking chloral hydrate has resulted in flushing, sweating, restlessness, nausea, increased blood pressure, and tachycardia in isolated cases. Chloroprocaine: Moderate Local anesthetics may cause additive hypotension in combination with antihypertensive agents. Chlorothiazide: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss.
Chlorpheniramine; Codeine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with codeine. Chlorpheniramine; Dextromethorphan; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Chlorpheniramine; Dihydrocodeine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Chlorpheniramine; Dihydrocodeine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Chlorpheniramine; Guaifenesin; Hydrocodone; Pseudoephedrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Chlorpheniramine; Hydrocodone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone.
Chlorpheniramine; Hydrocodone; Phenylephrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone.
Chlorpheniramine; Hydrocodone; Pseudoephedrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Chlorpheniramine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Chlorpheniramine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Chlorpropamide: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus. Chlorthalidone: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss. Chlorthalidone; Clonidine: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss.
The manufacturer of colestipol recommends administering other drugs at least 1 hour before or at least hours after the administration of colestipol and that the interval between the administration of colestipol and other drugs should be as long as possible. Cidofovir: Severe The administration of cidofovir with another potentially nephrotoxic agent, such as diuretics, is contraindicated.
Diuretics should be discontinued at least 7 days prior to beginning cidofovir. Cisapride: Major Cisapride should be used with great caution in patients receiving potassium-wasting diuretic therapies, such as loop diuretics. Drugs that are associated with depletion of electrolytes may cause cisapride-induced cardiac arrhythmias.
Cisatracurium: Moderate Furosemide-induced hypokalemia can potentiate neuromuscular blockade with nondepolarizing neuromuscular blockers. Cisplatin: Moderate Concurrent use of cisplatin and other agents known to be ototoxic e. Usually, reports indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, higher than recommended furosemide dosages or infusion rates, hypoproteinemia, or concomitant therapy with other ototoxic drugs.
Additive effects of cisplatin and loop diuretics on renal parameters and electrolyte balance should also be considered. Saline hydration and diuretic use are common during cisplatin therapy to manage hydration status.
If furosemide and cisplatin are used together, it is prudent to monitor renal function parameters and serum electrolyte concentrations during co-therapy. Audiologic monitoring may be advisable during high dose therapy or therapy of long duration, when hearing loss is suspected, or in selected risk groups. Citalopram: Moderate Citalopram causes dose-dependent QT interval prolongation.
Concurrent use of citalopram and medications known to cause electrolyte imbalance may increase the risk of developing QT prolongation. Therefore, caution is advisable during concurrent use of citalopram and diuretics. In addition, patients receiving a diuretic during treatment with citalopram may be at greater risk of developing syndrome of inappropriate antidiuretic hormone secretion SIADH. Hyponatremia may be potentiated by agents which can cause sodium depletion such as diuretics.
Discontinuation of citalopram should be considered in patients who develop symptomatic hyponatremia. Cocaine: Major Use of cocaine with antihypertensive agents may increase the antihypertensive effects of the antihypertensive medications or may potentiate cocaine-induced sympathetic stimulation.
Codeine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with codeine. Codeine; Guaifenesin: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with codeine. Codeine; Phenylephrine; Promethazine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with codeine.
Codeine; Promethazine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with codeine. CoQ10 use in combination with antihypertensive agents may lead to additional reductions in blood pressure in some individuals.
Patients who choose to take CoQ10 concurrently with antihypertensive medications should receive periodic blood pressure monitoring. Patients should be advised to inform their prescriber of their use of CoQ Colchicine; Probenecid: Moderate Probenecid can interfere with the natriuresis and plasma renin activity increases caused by diuretics such as furosemide.
Furosemide can in turn increase the levels of serum uric acid, antagonizing the effects of probenecid. Conivaptan: Moderate There is potential for additive hypotensive effects when conivaptan is coadministered with antihypertensive agents. Cosyntropin: Moderate Use cosyntropin cautiously in patients receiving diuretics.
Cosyntropin may accentuate the electrolyte loss associated with diuretic therapy. Cyclosporine: Moderate Coadministration of furosemide and cyclosporine increases the risk of gouty arthritis. This is a result of furosemide-induced hyperuricemia and the impairment of renal urate excretion by cyclosporine. Dapagliflozin: Moderate Loop diuretics can decrease the hypoglycemic effects of antidiabetic agents by producing an increase in blood glucose concentrations.
Patients receiving dapagliflozin should be monitored for changes in blood glucose control if such diuretics are added or deleted. Dapagliflozin; Metformin: Moderate Loop diuretics can decrease the hypoglycemic effects of antidiabetic agents by producing an increase in blood glucose concentrations.
Dapagliflozin; Saxagliptin: Moderate Loop diuretics can decrease the hypoglycemic effects of antidiabetic agents by producing an increase in blood glucose concentrations. Because of this, a potential pharmacodynamic interaction exists between these drugs and all antidiabetic agents.
Darifenacin: Minor Diuretics can increase urinary frequency, which may aggravate bladder symptoms. Dasabuvir; Ombitasvir; Paritaprevir; Ritonavir: Moderate The manufacturer of dasabuvir; ombitasvir; paritaprevir; ritonavir and ombitasvir; paritaprevir; ritonavir recommends caution and clinical monitoring if administered concurrently with furosemide.
Use of these drugs in combination has resulted in elevated furosemide maximum plasma concentrations Cmax. Individualize the dose of furosemide based on the patient's clinical response. The dose should be re-adjusted after completion of the hepatitis C treatment regimen. Moderate The manufacturer of dasabuvir; ombitasvir; paritaprevir; ritonavir recommends caution and clinical monitoring if administered concurrently with furosemide.
The dose should be re-adjusted after completion of the 4-drug hepatitis C treatment regimen. Desloratadine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Desmopressin: Major Desmopressin, when used in the treatment of nocturia is contraindicated with loop diuretics because of the risk of severe hyponatremia. Discontinuation of the SNRI should be considered in patients who develop symptomatic hyponatremia. Dexchlorpheniramine; Dextromethorphan; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Dexlansoprazole: Moderate Proton pump inhibitors have been associated with hypomagnesemia. Dexmethylphenidate: Moderate Dexmethylphenidate can reduce the hypotensive effect of antihypertensive agents, including loop diuretics.
Periodic evaluation of blood pressure is advisable during concurrent use of dexmethylphenidate and antihypertensive agents, particularly during initial coadministration and after dosage increases of dexmethylphenidate.
Dextroamphetamine: Minor Amphetamine and Dextroamphetamine may increase both systolic and diastolic blood pressure and may counteract the activity of some antihypertensive agents, such as loop diuretics. Dextromethorphan; Diphenhydramine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Dextromethorphan; Guaifenesin; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Dextromethorphan; Guaifenesin; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Dextromethorphan; Quinidine: Moderate Quinidine can decrease blood pressure and should be used cautiously in patients receiving antihypertensive agents due to the potential for additive hypotension.
Diazoxide: Moderate Additive hypotensive effects can occur with the concomitant administration of diazoxide with loop diuretics.
This interaction can be therapeutically advantageous, but dosages must be adjusted accordingly. The manufacturer advises that IV diazoxide should not be administered to patients within 6 hours of receiving other antihypertensive agents. Dichlorphenamide: Moderate Concomitant use of dichlorphenamide and furosemide is not recommended because of an increased risk of furosemide-related adverse effects and risk for hypokalemia.
Monitor closely for signs of drug toxicity if coadministration cannot be avoided in some patients furosemide dose adjustment might be necessary. Increased furosemide exposure is possible. Dichlorphenamide inhibits OAT1. Furosemide is an OAT1 substrate. Dichlorphenamide also increases potassium excretion and can cause hypokalemia and should be used cautiously with other drugs that may cause hypokalemia including furosemide. Measure potassium concentrations at baseline and periodically during dichlorphenamide treatment.
If hypokalemia occurs or persists, consider reducing the dose or discontinuing dichlorphenamide therapy. Diclofenac: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Diclofenac; Misoprostol: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.
Dicloxacillin: Minor Furosemide may compete with penicillin for renal tubular secretion, increasing penicillin serum concentrations. Diethylpropion: Major Diethylpropion has vasopressor effects and may limit the benefit of loop diuretics. Although leading drug interaction texts differ in the potential for an interaction between diethylpropion and this group of antihypertensive agents, these effects are likely to be clinically significant and have been described in hypertensive patients on these medications.
Diflunisal: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Digitoxin: Moderate Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics, increasing the risk of proarrhythmic effects of cardiac glycosides.
Digoxin: Moderate Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics, increasing the risk of proarrhythmic effects of cardiac glycosides.
Dihydrocodeine; Guaifenesin; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Diphenhydramine; Hydrocodone; Phenylephrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone.
Diphenhydramine; Ibuprofen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.
Diphenhydramine; Naproxen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Diphenhydramine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Docusate Sodium; Senna: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives. Docusate: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives.
Dofetilide: Major Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics increasing the potential for dofetilide-induced torsade de pointes. Potassium levels should be within the normal range prior and during administration of dofetilide. Dolasetron: Moderate Caution is advisable during concurrent use of dolasetron and loop diuretics as electrolyte imbalance caused by diuretics may increase the risk of QT prolongation with dolasetron.
Doxacurium: Moderate Furosemide-induced hypokalemia can potentiate neuromuscular blockade with nondepolarizing neuromuscular blockers. Droperidol: Moderate Caution is advised when using droperidol in combination with loop diuretics which may lead to electrolyte abnormalities, especially hypokalemia or hypomagnesemia, as such abnormalities may increase the risk for QT prolongation or cardiac arrhythmias.
Dulaglutide: Minor Loop diuretics, such as bumetanide, furosemide, and torsemide, may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Empagliflozin: Moderate When empagliflozin is initiated in patients already receiving loop diuretics, volume depletion can occur.
Furosemide controls but does not cure hypertension. To view other topics, please log in or purchase a subscription. Nursing Central is an award-winning, complete mobile solution for nurses and students. Complete Product Information.
Download the Nursing Central app by Unbound Medicine. We're glad you have enjoyed Nursing Central! As a thank-you for using our site, here's a discounted rate for renewal or upgrade. Not now - I'd like more time to decide. Renew my subscription. Davis's Drug Guide. Tags Type your tag names separated by a space and hit enter. Citation Vallerand, April Hazard. Davis Company, Nursing Central Redesign , nursing.
Davis Company; Accessed November 11, Vallerand, A.
0コメント